Latest Skystar Bio-Pharmaceutical Company (SKBI)

New Post Public Reply Private Reply Replies (0) Message Board

Mar 13, 2014 at 1:58 PM

Latest Skystar Bio-Pharmaceutical Company (SKBI) Headlines

Uptrend Call Working As Skystar Bio-Pharmaceutical Stock Rises 29.4% (SKBI)
Comtex SmarTrend(R) - Wed Mar 12, 11:01AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on February 11th, 2014 at $4.56. In approximately 4 weeks, Skystar Bio-Pharmaceutical has returned 29.39% as of today's recent price of $5.90.

40.1% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Wed Mar 05, 9:38AM CST
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on February 11th, 2014 at $4.56. In approximately 3 weeks, Skystar Bio-Pharmaceutical has returned 40.13% as of today's recent price of $6.39.

Shares of SKBI Up 22.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:15AM CST
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on February 11th, 2014 at $4.56. In approximately 2 weeks, Skystar Bio-Pharmaceutical has returned 22.81% as of today's recent price of $5.60.

5 Stocks Ready to Explode Higher
at The Street - Wed Feb 12, 1:13PM CST
These stocks could be sett9ing up for explosive moves higher soon.

4 Biotech Stocks Under $10 Making Big Moves
at The Street - Wed Jan 29, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.

Skystar Bio-Pharmaceutical posts increased net income of USD3.7m in Q3 2013
M2 - Mon Nov 18, 3:06AM CST
Skystar Bio-Pharmaceutical Company (Nasdaq: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, on Friday reported unaudited net income of USD3.7m, or USD0.49 per fully diluted share, for the third quarter of fiscal year 2013, ended 30 September 2013.

Skystar Bio-Pharmaceutical Reports Third Quarter 2013 Results
Marketwire - Fri Nov 15, 4:00AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2013 earnings, for the period ended September 30, 2013.

Skystar Bio-Pharmaceutical to Host Third Quarter 2013 Earnings Webcast Live on Friday, November 15, 2013
ACCESSWIRE - Thu Nov 14, 8:36AM CST
XI'AN, CHINA - (ACCESSWIRE - November 14, 2013) - Skystar Bio-Pharmaceutical Company (SKBI) will host a live webcast to discuss the results of the third quarter 2013, to be held Friday, November 15, 2013 at 7:45 a.m. Eastern Time.

Skystar to File Financial Results for Third Quarter of Fiscal 2013 on Thursday, November 14, 2013
Marketwire - Thu Nov 14, 8:30AM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2013 on Thursday November 14, 2013 by close of the business day.

Skystar Bio-Pharmaceutical Reports Second Quarter 2013 Results
Marketwire - Wed Aug 14, 2:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2013 earnings, for the period ended June 30, 2013.

Skystar to File Financial Results for Second Quarter of Fiscal 2013 on Wednesday, August 14, 2013
Marketwire - Tue Aug 13, 4:00PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2013 on Wednesday August 14, 2013 at close of the business day.

Market Maker Surveillance Report. CIEN, CHTP, NLST, SKBI, MY, NPTN, Winning Stocks With Lowest Price Friction For Thursday, June 6th 2013
M2 - Fri Jun 07, 3:00AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 3815 companies with "abnormal" market making, 3439 companies with positive Friction Factors and 1883 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Ciena Corp (NASDAQ:CIEN), Chelsea Therapeutics International Ltd (NASDAQ:CHTP), Netlist Inc (NASDAQ:NLST), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), China Ming Yang Wind Power Group Ltd (NYSE:MY), NeoPhotonics Corp (NYSE:NPTN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Skystar Bio-Pharmaceutical Company posts lower net income of USD0.7m for Q1 2013
M2 - Fri May 17, 6:43AM CDT
Veterinary medicine company Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) stated on Thursday its net income of USD0.7m or USD0.09 per fully diluted share, for the first quarter fiscal year 2013.

Skystar Bio-Pharmaceutical Reports First Quarter 2013 Results
Marketwire - Thu May 16, 4:00AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited first quarter fiscal year 2013 earnings, for the fiscal period ended March 31, 2013.

Skystar to File Financial Results for First Quarter of 2013 on Wednesday, May 15, 2013
Marketwire - Tue May 14, 8:03AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the first quarter of the fiscal year 2013 on Wednesday May 15, 2013 at the end of the business day.

Skystar Bio-Pharmaceutical Reports Fiscal Year 2012 Financial Results
Marketwire - Tue Apr 02, 4:00AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced full financial results for fiscal year ended December 31, 2012.

Skystar to File Audited Financial Results for Full Fiscal Year 2012 on Monday April 1, 2013
Marketwire - Mon Apr 01, 8:01AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its audited financial results for the full fiscal year 2012 on Monday April 1, 2013 at the end of the business day.

MGN, SKBI, ZEP, GBF, MNOV, PYS Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Mar 27, 7:52AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Mines Management Inc (AMEX:MGN), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), Zep Inc (NYSE:ZEP), iShares Barclays Government/Credit Bond Fund (NYSE:GBF), MediciNova Inc (NASDAQ:MNOV), PPLUS Trust Series RRD-1 (NYSE

YS) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

Skystar Bio-Pharmaceutical Engages Protiviti, a Leading Provider of Consulting and Internal Audit Services
Marketwire - Tue Mar 26, 8:01AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, announced that on March 14, 2013 the Company engaged Protiviti, a leading provider of consulting and internal audit services, whose expertise will serve to extend Skystar's accounting team's knowledge of rules on internal controls, procedures and reporting related to U.S. listing.

JAG, SKBI, SHV, MAXY, SFNC, IAI Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Wed Jan 23, 7:53AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Jaguar Mining Inc (NYSE:JAG), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), iShares Barclays Short Treasury Bond Fund (NYSE:SHV), Maxygen Inc (NASDAQ:MAXY), SIMMONS FIRST NATIONAL CORPORATION (NASDAQ:SFNC), iShares Dow Jones US Broker-Dealers Index Fund (NYSE:IAI) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:

Skystar Bio-Pharmaceutical Company (SKBI) Stock Research Links

SKBI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

WhiteHorse Set to Redeem Its 2028 Notes Completely

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....